Table 1.
The influence of LCN2 on the response to radiotherapy and chemotherapy.
| Author | Year | Therapy Type | Cancer Type | LCN2 Role | Mechanism |
|---|---|---|---|---|---|
| Shiiba et al. (125) | 2013 | Radiotherapy | Oral Squamous Cell Carcinoma | Increases radioresistance | Possibly involved in PI3K/Akt pathway |
| Shiiba et al. (125) | 2013 | Radiotherapy | Lung Cancer | Increases radioresistance | Needs further research |
| Zhang et al. (126) | 2014 | Radiotherapy | Nasopharyngeal Carcinoma | Promotes radioresistance | Likely interacts with HIF1A |
| Yu et al. (127) | 2014 | Chemotherapy | Renal Cell Carcinoma | Mediates resistance to sunitinib | Mediates resistance to tyrosine kinase inhibitor |
| Zheng et al. (128) | 2009 | Chemotherapy | Glioblastoma | Implicated in resistance to BCNU | Role in Akt dephosphorylation, crucial for apoptosis sensitization |
| Monisha et al. (129) | 2018 | Chemotherapy | Oral Squamous Cell Carcinoma | Increases resistance to cisplatin | Reduces drug-induced oxidative stress |
| Chaudhary et al. (32) | 2021 | Chemotherapy | Colorectal Cancer | Enhances chemoresistance to 5FU | Inhibits ferroptosis by lowering iron levels and increasing glutathione peroxidase 4 and xCT expression |
| Kim et al. (130) | 2017 | Chemotherapy | Breast Cancer | Induces 5FU resistance via Wnt signaling | Participates in the activation of the Wnt signaling pathway |
| Shi et al. (131) | 2024 | Chemotherapy | Non-Small Cell Lung Cancer | Mediates resistance to almonertinib | Involves in LCN2-MMP-9 signaling pathway |
| Jiang et al. (132) | 2023 | Chemotherapy | Endometrial Cancer | Facilitates cisplatin(DDP) resistance | Regulated by HNRNPA2B1-mediated modifications influencing ferroptosis |
| Zhang et al. (133) | 2022 | Chemotherapy | Pancreatic Cancer | Regulates chemosensitivity to gemcitabine | Needs further research |
PI3K, Phosphoinositide 3-kinase; HIF1A, Hypoxia-inducible factor 1-alpha; Akt, Protein Kinase B (PKB); 5FU, 5-fluorouracil; xCT, cysteine glutamate antiporter; Wnt, Wingless/Integrated; MMP-9, Matrix metalloproteinase-9; HNRNPA2B1, N6-methyladenosine (m6A) “reader”.